中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 2
Feb.  2017
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2017  >  33(2): 359-363

Mechanism of radiofrequency ablation in treatment of hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2017.02.035

  • Department of Ultrasound,Shengjing Hospital of China Medical University

  • Received Date: 2016-09-18
  • Published Date: 2017-02-20
    Abstract
  • Hepatocellular carcinoma( HCC) is a malignant tumor with high incidence and mortality rates around the world.Radiofrequency ablation( RFA) is an effective therapy for HCC,especially in patients who experience recurrence after surgery for liver cancer,who are complicated by liver dysfunction and unable to undergo surgical resection,and who have multiple liver tumors and undergo palliative treatment.RFA can significantly improve patients' survival time and quality of life.This article reviews the mechanism of RFA in the treatment of HCC from the aspects of direct and indirect injuries and helps to further understand the role of RFA in local and systemic treatment of HCC,which has a potential value for multidisciplinary treatment of HCC in future.

     

    • FullText(HTML)
    • References(46)
  • [1]McG LYNN KA,PETRICK JL,LONDON WT.Global epidemiology of hepatocellular carcinoma:an emphasis on demographic and regional variability[J].Clin Liver Dis,2015,19(2):223-238.
    [2]EL-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology,2012,142(6):1264-1273.
    [3]WONG R,FRENETTE C.Updates in the management of hepatocellular carcinoma[J].Gastroenterol Hepatol(NY),2011,7(1):16-24.
    [4]FORNER A,LLOVET JM,BRUIX J.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.
    [5]AKOAD ME,POMFRET EA.Surgical resection and liver transplantation for hepatocellular carcinoma[J].Clin Liver Dis,2015,19(2):381-399.
    [6]Ministry of Health of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
    [7]ROSSI S.Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma[J].JIntervent Radiol,1993,8:97-103.
    [8]LENCIONI R.Loco-regional treatment of hepatocellular carcinoma[J].Hepatology,2010,52(2):762-773.
    [9]LIVRAGHI T,GOLDBERG SN,LAZZARONI S,et al.Small hepatocellular carcinoma:treatment with radio-frequency ablation versus ethanol injection[J].Radiology,1999,210(3):655-661.
    [10]NIKFARJAM M,MALCONTENTI-WILSON C,CHRISTOPHI C.Focal hyperthermia produces progressive tumor necrosis independent of the initial thermal effects[J].J Gastrointest Surg,2005,9(3):410-417.
    [11]MERTYNA P,HINES-PERALTA A,LIU Z,et al.Radiofrequency ablation:variability in heat sensitivity in tumors and tissues[J].J Vasc Interv Radiol,2007,18(5):647-654.
    [12]CHU KF,DUPUY DE.Thermal ablation of tumours:biological mechanisms and advances in therapy[J].Nat Rev Cancer,2014,14(3):199-208.
    [13]AHMED M,BRACE CL,LEE Jr FT,et al.Principles of and advances in percutaneous ablation[J].Radiology,2011,258(2):351-369.
    [14]ZHOU Y,HAN G,WANG Y,et al.Radiofrequency heat-enhanced chemotherapy for breast cancer:towards interventional molecular image-guided chemotherapy[J].Theranostics,2014,4(11):1145.
    [15]ZHANG F,LE T,WU X,et al.Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line:monitoring with dualmodality imaging---preclinical study[J].Radiology,2014,270(2):400-408.
    [16]DICKSON JA,CALDERWOOD SK.Temperature range and selective sensitivity of tumors to hyperthermia:a critical review[J].Ann N Y Acad Sci,1980,335(1):180-205.
    [17]OVERGAARD K,OVERGAARD J.Investigations on the possibility of a thermic tumour therapy.I.Short-wave treatment of a transplanted isologous mouse mammary carcinoma[J].Eur J Cancer,1972,8(1):65-78.
    [18]THOMSEN S.Pathologic analysis of photothermal and photomechanical effects of laser-tissue interactions[J].Photochem Photobiol,1991,53(6):825-835.
    [19]OVERGAARD J,SUIT HD.Time-temperature relationship in hyperthermic treatment of malignant and normal tissue in vivo[J].Cancer Res,1979,39(8):3248-3253.
    [20]MATTHEWSON K,COLERIDGE-SMITH P,O'SULLIVAN JP,et al.Biological effects of intrahepatic neodymium:yttrium-aluminum-garnet laser photocoagulation in rats[J].Gastroenterology,1987,93(3):550-557.
    [21]van HILLEGERSBERG R,de WITTE MT,KORT WJ,et al.Water-jet-cooled Nd:YAG laser coagulation of experimental liver metastases:correlation between ultrasonography and histology[J].Lasers Surg Med,1993,13(3):332-343.
    [22]YANG W,CUI M,LEE J,et al.Heat shock protein inhibitor,quercetin,as a novel adjuvant agent to improve radiofrequency ablation-induced tumor destruction and its molecular mechanism[J].Chin J Cancer Res,2016,28(1):19.
    [23]FENG H,ZENG Y,WHITESELL L,et al.Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity[J].Blood,2001,97(11):3505-3512.
    [24]MELCHER A,TODRYK S,HARDWICK N,et al.Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression[J].Nat Med,1998,4(5):581-587.
    [25]LANNEAU D,BRUNET M,FRISAN E,et al.Heat shock proteins:essential proteins for apoptosis regulation[J].J Cell Mol Med,2008,12(3):743-761.
    [26]CHALMIN F,LADOIRE S,MIGNOT G,et al.Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloidderived suppressor cells[J].J Clin Invest,2010,120(2):457-471.
    [27]SPISEK R,CHARALAMBOUS A,MAZUMDER A,et al.Bortezomib enhances dendritic cell(DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells:therapeutic implications[J].Blood,2007,109(11):4839-4845.
    [28]SCHUELLER G,KETTENBACH J,SEDIVY R,et al.Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model[J].Oncol Rep,2004,12(3):495-499.
    [29]SCHUELLER G,KETTENBACH J,SEDIVY R,et al.Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo[J].Int J Oncol,2004,24(3):609-613.
    [30]HAEN SP,GOUTTEFANGEAS C,SCHMIDT D,et al.Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation[J].Cell Stress Chaperones,2011,16(5):495-504.
    [31]TSAN MF,GAO B.Heat shock proteins and immune system[J].JLeukoc Biol,2009,85(6):905-910.
    [32]DUAN X,LI TF,ZHOU GF,et al.Transcatheter arterial embolization combined with radiofrequency ablation activates CD8+T-cell infiltration surrounding residual tumors in the rabbit VX2 liver tumors[J].Onco Targets Ther,2016,9:2835-2844.
    [33]THIMME R,NEAGU M,BOETTLER T,et al.Comprehensive analysis of the alpha-fetoprotein-specific CD8+T cell responses in patients with hepatocellular carcinoma[J].Hepatology,2008,48(6):1821-1833.
    [34]MIZUKOSHI E,YAMASHITA T,ARAI K,et al.Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J].Hepatology,2013,57(4):1448-1457.
    [35]BEHM B,DI FAZIO P,MICHL P,et al.Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation[J].Gut,2016,65(1):134-143.
    [36]ZERBINI A,PILLI M,PENNA A,et al.Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses[J].Cancer Res,2006,66(2):1139-1146.
    [37]ZERBINI A,PILLI M,FAGNONI F,et al.Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation[J].J Immunother,2008,31(3):271-282.
    [38]NOBUOKA D,MOTOMURA Y,SHIRAKAWA H,et al.Radiofrequency ablation for hepatocellular carcinoma induces glypican-3peptide-specific cytotoxic T lymphocytes[J].Int J Oncol,2012,40(1):63-70.
    [39]de BETHLENFALVA-HORA CE,MERTENS JC,PIGUET AC,et al.Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma[J].Clin Sci(Lond),2014,126(3):243-252.
    [40]SHI L,CHEN L,WU C,et al.PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J].Clin Cancer Res,2016,22(5):1173-1184.
    [41]IKEMOTO T,SHIMADA M,YAMADA S.Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation[J].Hepatol Res,2017,47(1):23-30.
    [42]ERINJERI JP,THOMAS CT,SAMOILIA A,et al.Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10[J].J Vasc Interv Radiol,2013,24(8):1105-1112.
    [43]ROZENBLUM N,ZEIRA E,BULVIK B,et al.Radiofrequency ablation:inflammatory changes in the periablative zone can induce global organ effects,including liver regeneration[J].Radiology,2015,276(2):416-425.
    [44]AHMED M,KUMAR G,MOUSSA M,et al.Hepatic radiofrequency ablation-induced stimulation of distant tumor growth is suppressed by c-Met inhibition[J].Radiology,2015,279(1):103-117.
    [45]AHMED M,KUMAR G,NAVARRO G,et al.Systemic siRNAnanoparticle-based drugs combined with radiofrequency ablation for cancer therapy[J].PLoS One,2015,10(7):e0128910.
    [46]YIN Y,NI CF,LI Z,et al.Therapeutic comparison between radiofrequency ablation and percutaneous ethanol injection in treatment of primary liver cancer:a meta-analysis[J].J Clin Hepatol,2015,31(6):918-921.(in Chinese)印于,倪才方,李智,等.射频消融与经皮无水乙醇注射治疗原发性肝癌疗效对比的Meta分析[J].临床肝胆病杂志,2015,31(6):918-921.
    • Relative Articles

  • Relative Articles

    [1]Kexin QIAO, Guiqin ZHOU, Yaxing LIU, Ying FENG, Yao LIU, Bin LI, Xianbo WANG. Clinical features of primary biliary cholangitis patients with negative or positive anti-mitochondrial antibody： A comparative study[J]. Journal of Clinical Hepatology, 2024, 40(9): 1778-1784. doi: 10.12449/JCH240910
    [2]Cui NaNa, Wang QiXia. Diagnosis and differential diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 724-727. doi: 10.3969/j.issn.1001-5256.2020.04.002
    [3]Zhang LiXia, Huang Xu, Sun XiaoJie, Zhang Ying, Lu ShaSha, Shi XiaoDong, Ji HuiFan, Guo XiaoLin. A case of antimitochondrial antibody-negative primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(1): 179-181. doi: 10.3969/j.issn.1001-5256.2019.01.038
    [4]Han Ying, Chen Jie, Dan Jing, Liu YanMin, Zhang XiaoDan, Ren MeiXin, Du XiaoFei, Bian XinQu, Liu Dan, Huang YunLi, Huang ChunYang, Liao HuiYu. Value of fumarate hydratase antibody in differential diagnosis of autoimmune hepatitis and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2019, 35(6): 1326-1329. doi: 10.3969/j.issn.1001-5256.2019.06.029
    [5]Liu HongLi, Yang YongFeng. Clinical and pathological features of primary biliary cholangitis with negative anti-mitochondrial antibody[J]. Journal of Clinical Hepatology, 2019, 35(3): 677-680. doi: 10.3969/j.issn.1001-5256.2019.03.051
    [6]Bian ZhaoLian, Shao JianGuo, Ma Xiong. Differential diagnosis of drug-induced liver injury and autoimmune hepatitis and related therapeutic strategies[J]. Journal of Clinical Hepatology, 2018, 34(6): 1156-1159. doi: 10.3969/j.issn.1001-5256.2018.06.003
    [7]Luo WenPing, Ma Hong, Zhao XinYan. Pathological features of hepatic vascular diseases and key points in differential diagnosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2289-2294. doi: 10.3969/j.issn.1001-5256.2018.11.005
    [8]Jiang LiLin, Shen JianBo, Tang Hong, Lu ZhongHua. Pathological differential diagnosis of inflammatory liver injury[J]. Journal of Clinical Hepatology, 2018, 34(11): 2278-2282. doi: 10.3969/j.issn.1001-5256.2018.11.003
    [9]Du XiaoFeng, Ma ZhouPeng, Lin GuanSheng, He Hui, Tang YaRong, Wu JianMing. CT diagnosis and differentiation of nodular/mass-type hepatic lymphoma[J]. Journal of Clinical Hepatology, 2017, 33(8): 1492-1496. doi: 10.3969/j.issn.1001-5256.2017.08.016
    [10]Li Jing, Tang ShaoShan, Yu HongWei. Value of contrast-enhanced ultrasound in differential diagnosis of single metastatic liver cancer and solitary necrotic nodule of the liver[J]. Journal of Clinical Hepatology, 2016, 32(7): 1338-1341. doi: 10.3969/j.issn.1001-5256.2016.07.025
    [11]Wang Sui, Wang JiangBin. The diagnosis and treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1605-1607. doi: 10.3969/j.issn.1001-5256.2015.10.010
    [12]Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis)(2015)[J]. Journal of Clinical Hepatology, 2015, 31(12): 1980-1988. doi: 10.3969/j.issn.1001-5256.2015.12.004
    [13]Zhang AnYuan, Chen Hao, Zhao Peng, Gong JianPing. Differential diagnosis of autoimmune pancreatitis from pancreatic cancer[J]. Journal of Clinical Hepatology, 2015, 31(5): 783-786. doi: 10.3969/j.issn.1001-5256.2015.05.038
    [14]Guo Jing, Xu LingFen, Sun Mei. Differential diagnosis of biliary atresia and intrahepatic cholestasis in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1252-1256. doi: 10.3969/j.issn.1001-5256.2015.08.017
    [15]Cao ZhangChun. Significance of combined analysis of autoantibodies in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 178-180. doi: 10.3969/j.issn.1001-5256.2015.02.008
    [16]Li YinPing, Niu JunQi. Significance of serum anti-gp210 antibody detection in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(5): 466-468. doi: 10.3969/j.issn.1001-5256.2014.05.023
    [17]Zhao DanTong, Liao HuiYu, Liu YanMin, Huang ChunYang, Zhang HaiPing, Sun LiMei, Ma YinXue, Zhao Yan, Yan HuiPing. ROC analysis of prognostic factors in Chinese patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(1): 62-66. doi: 10.3969/j.issn.1001-5256.2014.01.017
    [18]Li Bing, Shao Qing, Niu XiaoXia, Zhang Jian, Chen GuoFeng. Clinical features and diagnosis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome[J]. Journal of Clinical Hepatology, 2014, 30(5): 413-416. doi: 10.3969/j.issn.1001-5256.2014.05.007
    [19]Zhang Li, Bai ShiShan. Research progress on laboratory diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1109-1111+1120.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.4 %FULLTEXT: 15.4 %META: 75.2 %META: 75.2 %PDF: 9.3 %PDF: 9.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.7 %其他: 8.7 %其他: 1.8 %其他: 1.8 %Central District: 0.1 %Central District: 0.1 %China: 0.9 %China: 0.9 %India: 0.9 %India: 0.9 %Jamaica Plain: 0.1 %Jamaica Plain: 0.1 %Rochester: 0.1 %Rochester: 0.1 %Russian Federation: 0.1 %Russian Federation: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.6 %[]: 0.6 %上海: 3.2 %上海: 3.2 %东莞: 0.3 %东莞: 0.3 %临汾: 0.1 %临汾: 0.1 %丽水: 0.1 %丽水: 0.1 %佛山: 0.2 %佛山: 0.2 %信阳: 0.2 %信阳: 0.2 %北京: 3.3 %北京: 3.3 %南京: 0.9 %南京: 0.9 %南宁: 0.7 %南宁: 0.7 %南平: 0.1 %南平: 0.1 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %吉打州: 0.3 %吉打州: 0.3 %吉林: 0.4 %吉林: 0.4 %哥伦布: 0.1 %哥伦布: 0.1 %大连: 0.6 %大连: 0.6 %天津: 0.3 %天津: 0.3 %太原: 0.1 %太原: 0.1 %宝鸡: 0.2 %宝鸡: 0.2 %岳阳: 0.1 %岳阳: 0.1 %常德: 0.1 %常德: 0.1 %广州: 2.6 %广州: 2.6 %张家口: 5.1 %张家口: 5.1 %徐州: 0.1 %徐州: 0.1 %成都: 1.1 %成都: 1.1 %拉贾斯坦邦: 0.1 %拉贾斯坦邦: 0.1 %新泽西州: 0.3 %新泽西州: 0.3 %昆明: 0.7 %昆明: 0.7 %晋城: 0.1 %晋城: 0.1 %杭州: 1.0 %杭州: 1.0 %武汉: 1.2 %武汉: 1.2 %法兰克福: 0.2 %法兰克福: 0.2 %法拉盛: 0.2 %法拉盛: 0.2 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.2 %海得拉巴: 0.2 %深圳: 0.4 %深圳: 0.4 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %澳门: 0.3 %澳门: 0.3 %琼海: 0.2 %琼海: 0.2 %石家庄: 1.3 %石家庄: 1.3 %福州: 0.1 %福州: 0.1 %芒廷维尤: 35.6 %芒廷维尤: 35.6 %芝加哥: 0.1 %芝加哥: 0.1 %莫斯科: 2.2 %莫斯科: 2.2 %衢州: 0.1 %衢州: 0.1 %西孟加拉邦: 0.1 %西孟加拉邦: 0.1 %西宁: 14.7 %西宁: 14.7 %西安: 0.4 %西安: 0.4 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.8 %运城: 1.8 %通辽: 0.2 %通辽: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 1.4 %长春: 1.4 %长沙: 0.9 %长沙: 0.9 %阿什本: 0.3 %阿什本: 0.3 %香港: 0.3 %香港: 0.3 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.1 %黄冈: 0.1 %其他其他Central DistrictChinaIndiaJamaica PlainRochesterRussian FederationUnited States[]上海东莞临汾丽水佛山信阳北京南京南宁南平南阳卡纳塔克吉打州吉林哥伦布大连天津太原宝鸡岳阳常德广州张家口徐州成都拉贾斯坦邦新泽西州昆明晋城杭州武汉法兰克福法拉盛济南海得拉巴深圳湘潭漯河澳门琼海石家庄福州芒廷维尤芝加哥莫斯科衢州西孟加拉邦西宁西安贵阳赤峰运城通辽重庆长春长沙阿什本香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2401) PDF downloads(608) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[189]TodayPV[384]Online[25]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return